留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

黄褐斑的治疗进展

李芸 孙秋宁

李芸, 孙秋宁. 黄褐斑的治疗进展[J]. 协和医学杂志, 2012, 3(4): 476-481. doi: 10.3969/j.issn.1674-9081.2012.04.025
引用本文: 李芸, 孙秋宁. 黄褐斑的治疗进展[J]. 协和医学杂志, 2012, 3(4): 476-481. doi: 10.3969/j.issn.1674-9081.2012.04.025

黄褐斑的治疗进展

doi: 10.3969/j.issn.1674-9081.2012.04.025
详细信息
    通讯作者:

    孙秋宁 电话:010-69151544, E-mail:sunqnzhy@yahoo.com

  • 中图分类号: R751.05

  • [1] Vazquez M, Maldonado H, Benmaman C, et al. Melasma in men. A clinical and histologic study[J]. Int J Dermatol, 1988, 27:25-27. doi:  10.1111/j.1365-4362.1988.tb02329.x
    [2] Sanchez NP, Pathak MA, Sato S, et al. Melasma:a clini-cal, light microscopic, ultrastructural, and immunofluorescence study[J]. J Am Acad Dermatol, 1981, 4:698-710. doi:  10.1016/S0190-9622(81)70071-9
    [3] Gupta AK, Gover MD, Nouri K, et al. The treatment of melasma:a review of clinical trials[J]. J Am Acad Dermatol, 2006, 55:1048-1065. doi:  10.1016/j.jaad.2006.02.009
    [4] Department of Health and Human Services. Food and Drug Administration. Skin bleaching drug products for over-thecounter human use; proposed rule[J]. Federal Register, 2006, 71: 51146-51155.
    [5] Grimes PE, Bhawan J, Guevara IL, et al. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma[J]. J Am Acad Dermatol, 2010, 62:962-967. doi:  10.1016/j.jaad.2009.06.067
    [6] Ferreira Cestari T, Hassun K, Sittart A, et al. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma[J]. J Cosmet Dermatol, 2007, 6:36-39. doi:  10.1111/j.1473-2165.2007.00288.x
    [7] Lee JH, Park JG, Lim SH, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients:a preliminary clinical trial[J]. Dermatol Surg, 2006, 32:626-631. doi:  10.1111/j.1524-4725.2006.32133.x
    [8] Navarrete-Solís J, Castanedo-Cázares JP, Torres-Álvarez B, et al. A double-blind, randomized clinical trial of niacinamide 4% versus hydroquinone 4% in the treatment of melasma[J]. Dermatol Res Pract, 2011, 2011:379173. http://www.ncbi.nlm.nih.gov/pubmed/21822427
    [9] Ertam I, Mutlu B, Unal I, et al. Efficiency of ellagic acid and arbutin in melasma:a randomized, prospective, openlabel study[J]. J Dermatol, 2008, 35:570-574. doi:  10.1111/j.1346-8138.2008.00522.x
    [10] Kim DS, Kim SY, Park SH, et al. Inhibitory effects of 4-nbutylresorcinol on tyrosinase activity and melanin synthesis[J]. Biol Pharm Bull, 2005, 28:2216-2219. doi:  10.1248/bpb.28.2216
    [11] Khemis A, Kaiafa A, Queille-Roussel C, et al. Evaluation of efficacy and safety of rucinol serum in patients with melasma:a randomized controlled trial[J]. Br J Dermatol, 2007, 156:997-1004. doi:  10.1111/j.1365-2133.2007.07814.x
    [12] Huh SY, Shin JW, Na JI, et al. Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma:a randomized controlled split-face trial[J]. J Dermatol, 2010, 37:311-315. doi:  10.1111/j.1346-8138.2010.00787.x
    [13] Alvin G, Catambay N, Vergara A, et al. A comparative study of the safety and efficacy of 75% mulberry (Morus alba) extract oil versus placebo as a topical treatment for melasma:a randomized, single-blind, placebo-controlled trial[J]. J Drugs Dermatol, 2011, 10:1025-1031.
    [14] Erbil H, Sezer E, Tastan B, et al. Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma[J]. J Dermatol, 2007, 34:25-30. doi:  10.1111/j.1346-8138.2007.00211.x
    [15] Abu Ubeid A, Zhao L, Wang Y, et al. Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase[J]. J Invest Dermatol, 2009, 129:2242-2249. doi:  10.1038/jid.2009.124
    [16] Hantash BM, Jimenez F. A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma[J]. J Drugs Dermatol, 2009, 8:732-735. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=df69eacfb56c53393a921e294acc57ad
    [17] Ilknur T, Bicak MU, Demirtasoglu M, et al. Glycolic acid peels versus amino fruit acid peels in the treatment of melasma[J]. Dermatol Surg, 2010, 36:490-495. doi:  10.1111/j.1524-4725.2010.01481.x
    [18] Garg VK, Sarkar R, Agarwal R. Comparative evaluation of beneficiary effects of priming agents (2% hydroquinone and 0.025% retinoic acid) in the treatment of melasma with glycolic acid peels[J]. Dermatol Surg, 2008, 34:1032-1039.
    [19] Ejaz A, Raza N, Iftikhar N, et al. Comparison of 30% salicylic acid with Jessner's solution for superficial chemical peeling in epidermal melasma[J]. J Coll Physicians Surg Pak, 2008, 18:205-208. http://europepmc.org/abstract/MED/18474151
    [20] Kodali S, Guevara IL, Carrigan CR, et al. A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women[J]. J Am Acad Dermatol, 2010, 63:1030-1035. doi:  10.1016/j.jaad.2009.12.027
    [21] Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner's solution chemical peels[J]. Dermatol Surg, 2006, 32:1429-1436.
    [22] Azzam OA, Leheta TM, Nagui NA, et al. Different therapeutic modalities for treatment of melasma[J]. J Cosmet Dermatol, 2009, 8:275-281. doi:  10.1111/j.1473-2165.2009.00471.x
    [23] Safoury OS, Zaki NM, El Nabarawy EA, et al. A study comparing chemical peeling using modified Jessner's solution and 15% trichloroacetic acid versus 15% trichloroacetic acid in the treatment of melasma[J]. Indian J Dermatol, 2009, 54:41-45. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=PubMed000002243130
    [24] Trelles MA, Velez M, Gold MH. The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two:a comparative study[J]. J Drugs Dermatol, 2010, 9:315-322.
    [25] Jang WS, Lee CK, Kim BJ, et al. Efficacy of 694-nm Qswitched ruby fractional laser treatment of melasma in female Korean patients[J]. Dermatol Surg, 2011, 37:1133-1140. doi:  10.1111/j.1524-4725.2011.02018.x
    [26] Chang CJ, Kou CS. Comparing the effectiveness of Q-switched Ruby laser treatment with that of Q-switched Nd:YAG laser for oculodermal melanosis (Nevus of Ota)[J]. J Plast Reconstr Aesthet Surg, 2011, 64:339-345. doi:  10.1016/j.bjps.2010.05.036
    [27] Polnikorn N. Treatment of refractory dermal melasma with the MedLite C6 Q-switched Nd:YAG laser:two case reports[J]. J Cosmet Laser Ther, 2008, 10:167-173. doi:  10.1080/14764170802179687
    [28] Cho SB, Kim JS, Kim MJ. Melasma treatment in Korean women using a 1064-nm Q-switched Nd:YAG laser with low pulse energy[J]. Clin Exp Dermatol, 2009, 34:e847-e850. doi:  10.1111/j.1365-2230.2009.03599.x
    [29] Jeong SY, Shin JB, Yeo UC, et al. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre-or post-treatment triple combination cream[J]. Dermatol Surg, 2010, 36:909-918. doi:  10.1111/j.1524-4725.2010.01523.x
    [30] Wattanakrai P, Mornchan R, Eimpunth S. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1, 064 nm) laser for the treatment of facial melasma in Asians[J]. Dermatol Surg, 2010, 36:76-87. doi:  10.1111/j.1524-4725.2009.01383.x
    [31] Rahman Z, Alam M, Dover JS. Fractional laser treatment for pigmentation and texture improvement[J]. Skin Therapy Lett, 2006, 11:7-11. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=17075654
    [32] Goldberg DJ, Berlin AL, Phelps R. Histologic and ultrastructural analysis of melasma after fractional resurfacing[J]. Lasers Surg Med, 2008, 40:134-138. doi:  10.1002/lsm.20591
    [33] Kroon MW, Wind BS, Beek JF, et al. Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma:A randomized controlled pilot study[J]. J Am Acad Dermatol, 2011, 64:516-523. doi:  10.1016/j.jaad.2010.01.048
    [34] Wind BS, Kroon MW, Meesters AA, et al. Non-ablative 1, 550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma:a randomized controlled split-face study[J]. Lasers Surg Med, 2010, 42:607-612. doi:  10.1002/lsm.20937
    [35] Li YH, Chen JZS, Wei HC, et al. Efficacy and safety of intense pulsed light in treatment of melasma in Chinese patients[J]. Dermatol Surg, 2008, 34:693-701. doi:  10.1111/j.1524-4725.2008.34130.x
    [36] Goldman MP, Gold MH, Palm MD, et al. Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma[J]. Dermatol Surg, 2011, 37:224-233. doi:  10.1111/j.1524-4725.2010.01849.x
    [37] Ni Z, Mu Y, Gulati O. Treatment of melasma with Pycnogenol[J]. Phytother Res, 2002, 16:567-571. doi:  10.1002/ptr.1085
    [38] Handog EB, Galang DA, de Leon-Godinez MA, et al. A randomized, double-blind, placebo-controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women[J]. Int J Dermatol, 2009, 48:896-901. doi:  10.1111/j.1365-4632.2009.04130.x
    [39] Shi HF, Xu B, Guo XC, et al. Effect of Gan-Pi regulatory needling in treating chloasma[J]. Chin J Integr Med, 2010, 16:66-70. doi:  10.1007/s11655-010-0066-3
    [40] Feng XJ, Fu JY, Liu F. Clinical observation on the combined use of acupuncture and herbal medicine for treatment of chloasma[J]. J Tradit Chin Med, 2010, 30:15-17. doi:  10.1016/S0254-6272(10)60004-0
  • 加载中
计量
  • 文章访问数:  247
  • HTML全文浏览量:  35
  • PDF下载量:  45
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-08-01
  • 刊出日期:  2012-10-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!